Obesity and cancer: The risks, science, and potential management strategies

ONCOLOGY

Volumn 19, Issue 7, 2005, Pages 871-881

  McTiernan, Anne ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ESTROGEN; INSULIN; LEPTIN; SOMATOMEDIN; TESTOSTERONE;

ADIPOSE TISSUE; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DIET; DISEASE ASSOCIATION; HUMAN; OBESITY; PHYSICAL ACTIVITY; POSTOPERATIVE COMPLICATION; PROGNOSIS; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; INSULIN RESISTANCE; NEOPLASM; RISK FACTOR;

ANIMALS; HUMANS; INSULIN RESISTANCE; NEOPLASMS; OBESITY; RISK FACTORS; WEIGHT LOSS;

EID: 27144507976     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. International Agency for Research on Cancer Working Group on the Evaluation of Cancer-Preventive Agents: Weight control and physical activity. IARC Handbooks of Cancer Prevention, Vol 6. Lyon, International Agency for Research on Cancer, 2002.
2. Chlebowski RT, Aiello E, McTiernan A: Weight loss in breast cancer patient management. J Clin Oncol 20:1128-1143, 2002.
3. Brown JK, Byers T, Doyle C, et al: Nutrition and physical activity during and after cancer treatment: An American Cancer Society guide for informed choices. CA Cancer J Clin 53:268-291, 2003.
4. Flegal KM, Carroll MD, Kuczmarski RJ, et al: Overweight and obesity in the United States: Prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 22:39-47, 1998.
5. Calle EE, Rodriguez C, Walker-Thurmond K, et al: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625-1638, 2003.
6. Folsom A, Kaye S, Sellers T, et al: Body fat distribution and 5-year risk of death in older women. JAMA 269:483-487, 1993.
7. Calle E, Kaaks R: Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579-591, 2004.
8. van den Brandt P, Spiegelman D, Yaun S-S, et al: Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152:514-527, 2000.
9. Morimoto LM, White E, Chen Z, et al: Obesity, body size, and risk of postmenopausal breast cancer: The Women's Health Initiative (United States). Cancer Causes Control 13:741-751, 2002.
10. Meyerhardt J, Catalano P, Haller D, et al: Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 98:484-495, 2003.
11. Freedland S, Aronson W, Kane C, et al: Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: A report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 22:446-453, 2004.
12. Amling C, Riffenburgh R, Sun L, et al: Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22:439-445, 2004.
13. Reeves M, Newcomb P, Remington P, et al: Body mass and breast cancer. Relationship between method of detection and stage of disease. Cancer 77:301-307, 1996.
14. Wee C, McCarthy E, Davis R, et al: Screening for cervical and breast cancer: Is obesity an unrecognized barrier to preventive care? Ann Intern Med 132:697-704, 2000.
15. Baumgartner K, Baumgartner R, WC Hunt W, et al: Association of body composition and weight history with breast cancer prognostic markers: A divergent pattern between Hispanic and non-Hispanic white women. Am J Epidemiol 160:1087-1097, 2004.
16. Dignam JJ, Wieand K, Johnson KA, et al: Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95:1467-1476, 2003.
17. Berclaz G, Li S, Price KN, et al: Body mass index as a prognostic feature in inoperable breast cancer: The International Breast Cancer Study Group experience. Ann Oncol 15:875-884, 2004.
18. Goodwin PJ, Esplen MJ, Winocur J, et al: Development of a weight management program in women with newly diagnosed locoregional breast cancer, in: Bitzer J, Stauber M (eds): Psychosomatic Obstetrics and Gynecology, pp 491-496. Bologna (Italy), Monduzzi Editore, International Proceedings Division, 1995.
19. Chang S, Alderfer J, Asmar L, et al: Inflammatory breast cancer survival: The role of obesity and menopausal status at diagnosis. Breast Cancer Res Treat 64:157-163, 2001.
20. Goodwin PJ, Ennis M, Pritchard KI, et al: Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. J Clin Oncol 20:42-51, 2002.
21. Borugian M, Sheps S, Kim-Sing C, et al: Waist-to-hip ratio and breast cancer mortality. Am J Epidemiol 158:963-968, 2003.
22. Kumar N, Cantor A, Allen K, et al: Android obesity at diagnosis and breast carcinoma survival: Evaluation of the effects of anthropometric variables at diagnosis, including body composition and body fat distribution and weight gain during life span, and survival from breast carcinoma. Cancer 88:2751-2757, 2000.
23. Li CI, Malone KE, Porter PL, et al: Epidemiologic and molecular risk factors for contralateral breast cancer among young women. Br J Cancer 89:513-518, 2003.
24. Schips L, Lipsky K, Zigeuner R, et al: Does overweight impact on the prognosis of patients with renal cell carcinoma? A single center experience of 683 patients. J Surg Oncol 88:57-61, 2004.
25. Kamat A, Shock R, Naya Y, et al: Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology 63:46-50, 2004.
26. Goodwin PJ, Ennis M, Pritchard KI, et al: Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol 17:120-129, 1999.
27. Irwin ML, Crumley D, McTiernan A, et al: Physical activity levels before and after a diagnosis of breast carcinoma: The Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer 97:1746-1757, 2003.
28. Rock C, McEligot A, Flatt S: Eating pathology and obesity in women at risk for breast cancer recurrence. Int J Eat Disord 27:172-179, 2000.
29. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998.
30. Demark-Wahnefried W, Winer E, Rimer B: Why women gain weight with adjuvant chemotherapy for breast cancer (review). J Clin Oncol 11:1418-1429, 1993.
31. Shepherd L, Parulekar W, Day A: Weight gain during adjuvant therapy in high risk pre/perimenopausal breast cancer patients: Analysis of a National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Phase III Study (abstract). Proc Am Soc Clin Oncol 20:36a, 2001.
32. Bernstein L, Deapen D, Cerhan JR, et al: Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91:1654-1662, 1999.
33. Yancik R, Wesley MN, Ries LA, et al: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885-892, 2001.
34. Lu-Yao G, Stukel T, Yao S: Changing patterns in competing causes of death in men with prostate cancer: A population based study. J Urol 171:2285-2290, 2004.
35. Ganz PA, Rowland JH, Meyerowitz BE, et al: Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res 152:396-411, 1998.
36. Courneya KS: Exercise in cancer survivors: An overview of research. Med Sci Sports Exerc 35:1846-1852, 2003.
37. Howell A, on behalf of the ATAC Trialists' Group A: The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer - Updated efficacy results based on a median follow-up of 5 years. Breast Cancer Res Treat 88(1 suppl), 2004.
38. Chlebowski RT, Col N, Winer EP, et al: American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 20:3328-3343, 2002.
39. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: Re-analysis of nine prospective studies. J Natl Cancer Inst 94:606-616, 2002.
40. McTiernan A, Rajan KB, Tworoger SS, et al: Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol 21:1961-1966, 2003.
41. Irwin ML, Yasui Y, Ulrich CM, et al: Effect of exercise on total and intra-abdominal body fat in postmenopausal women: A randomized controlled trial. JAMA 289:323-330, 2003.
42. McTiernan A, Ulrich C, Kumai C, et al: Anthropometric and hormone effects of an eight-week exercise-diet intervention in breast cancer patients: Results of a pilot study. Cancer Epidemiol Biomarkers Prev 7:477-481, 1998.
43. Shade E, Ulrich C, Wener M, et al: Frequent intentional weight loss is associated with lower natural killer cell cytotoxicity in postmenopausal women: Possible long-term immune effects. J Am Diet Assoc 104:903-912, 2003.
44. Nieman DC, Cook VD, Henson DA, et al: Moderate exercise training and natural killer cell cytotoxic activity in breast cancer patients. Int J Sports Med 16:334-337, 1995.
45. Obesity Education Initiative: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report, Executive Summary. Bethesda, Md, National Heart, Lung, and Blood Institute, 1998.
46. Knowler WC, Barrett-Connor E, Fowler SE, et al: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002.
47. McTigue KM, Harris R, Hemphill B, et al: Screening and interventions for obesity in adults: Summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 139:933-949, 2003.
48. Samaha FF, Iqbal N, Seshadri P, et al: A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 348:2074-2081, 2003.
49. Foster GD, Wyatt HR, Hill JO, et al: A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 348:2082-2090, 2003.
50. Arterburn D, Noel P: Effects of drug treatment for obesity in adults. Clin Evid 412-419, 2001.
51. Brolin RE: Bariatric surgery and long-term control of morbid obesity. JAMA 288:2793-2796, 2002.
52. Pronk NP, Wing RR: Physical activity and long-term maintenance of weight loss. Obes Res 2:587-599, 1994.
53. Wilmore JH: Increasing physical activity: Alterations in body mass and composition. Am J Clin Nutr 63(3 suppl):456S-460S, 1996.
54. Loprinzi CL, Athmann LM, Kardinal CG, et al: Randomized trial of dietician counseling to try to prevent weight gain associated with breast cancer adjuvant chemotherapy. Oncology (Basel) 53:228-232, 1996.
55. Djuric Z, DiLaura NM, Jenkins I, et al: Combining weight-loss counseling with the weight watchers plan for obese breast cancer survivors. Obes Res 10:657-665, 2002.
56. Jen K, Djuric Z, DiLaura N, et al: Improvement of metabolism among obese breast cancer survivors in differing weight loss regimens. Obes Res 12:306-312, 2004.
57. de Waard F, Ramlau R, Mulders Y, et al: A feasibility study on weight reduction in obese postmenopausal breast cancer patients. Eur J Cancer Prev 2:233-238, 1993.
58. Chlebowski RT, Blackburn GL, Buzzard IM, et al: Adherence to a dietary fat intake reduction program in postmenopausal women receiving therapy for early breast cancer. The Women's Intervention Nutrition Study. J Clin Oncol 11:2072-2080, 1993.
59. Pierce JP, Faerber S, Wright FA, et al: Feasibility of a randomized trial of a high-vegetable diet to prevent breast cancer recurrence. Nutr Cancer 28:282-288, 1997.
60. Chlebowski RT, Blackburn G, Winters B, et al: Long term adherence to dietary fat reduction in the Women's Intervention Nutrition Study (abstract 302). Proc Am Soc Clin Oncol 19:78a, 2000.
61. Thomson C, Rock C, Giuliano A, et al: Longitudinal changes in body weight and body composition among women previously treated for breast cancer consuming a high-vegetable, fruit and fiber, low-fat diet. Eur J Nutr 5:1-8, 2004.
62. Ornish DM, Lee KL, Fair WR, et al: Dietary trial in prostate cancer: Early experience and implications for clinical trial design. Urology 57(4 suppl 1):200-201, 2001.